Thursday, January 14th 2021
This important contract signed with a major veterinary vaccine company will allow to develop the studies ongoing and is an important step for both companies declares Pr Didier Betbeder
...Read moreWednesday, December 23rd 2020
Vaxinano announces the signature of a new contract with a vaccine veterinary company. This contract demonstrates the interest of this company to pursue studies with our technology declares Pr Didier Betbeder.
...Read moreTuesday, October 20th 2020
« This is a great news for the company that allows to go further for the development of our vaccines for clinical trials announces Pr Didier Bebeder »
...Read moreFriday, October 16th 2020
In this article, Vaxinano and the laboratory BioMAP (INRAE) have vaccinated non-human primates against toxoplasmosis with the support of french zoos.
...Read moreWednesday, September 09th 2020
In this publication, Vaxinano’s nasal vaccine administered using a nasal spray protects sheep against chronic and congenital Toxoplasma gondii infection (Ducournau C. & al. Front. Immunol. 2020). This vaccine will also benefit the general public health by reducing the socio-economic burden associated to the consumption of contaminated meat, the major source of human toxoplasmosis.
...Read moreMonday, August 03rd 2020
Mucus is a natural barrier that impedes pathogens to invade the body and initiate infection. Contrary to most nanocarriers, Vaxinano’s starch nanoparticles are able to cross the mucus layer and induce an immune protective response (Fasquelle F. & al., ACS Appl. Bio Mater. 2020). This explains why Vaxinano’s vaccines are efficient via the mucosal administration route, acting against a large number of pathogens - such as Influenza viruses and Toxoplasma gondii - without the addition of any adjuvants (Le MQ. & al., Int. J. Pharm. 2020; Ducournau C. & al., Front. Immunol. 2020).
...Read moreTuesday, June 30th 2020
The French research national agency (ANR) has granted Vaxinano funding to develop an innovative vaccine against Covid-19.
...Read moreThursday, April 16th 2020
Nasal vaccination with Vaxinano's nanoparticles against flu virus inhibits virus transmission
...Read moreWednesday, February 12th 2020
Didier Betbeder, CEO & CSO of Vaxinano, explains how innovative and efficient is its vaccine platform.
...Read moreThursday, January 16th 2020
Didier Betbeder, CEO & CSO of Vaxinano, presents the vaccine platform to Vaccinology Club of the French Society for Immunology
...Read more